Skip to main content

Advertisement

SpringerLink
Log in

Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

  • Case Report
  • Published:
Modern Rheumatology

Abstract

Pyoderma gangrenosum (PG) is characterized by ulcerative skin lesions. Infliximab (IFX) may promote PG healing in patients with inflammatory bowel disease, but whether IFX is effective for treating PG in patients with rheumatoid arthritis (RA) has not reported. We report the case of a 53-year-old woman with PG complicated by RA who was treated using IFX therapy. This case suggests that IFX therapy might offer effective treatment for such patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–5.

    Article  CAS  PubMed  Google Scholar 

  2. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–58.

    Article  PubMed  Google Scholar 

  3. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79:37–46.

    Article  CAS  Google Scholar 

  4. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–22.

    Article  CAS  PubMed  Google Scholar 

  5. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000–5.

    Article  PubMed  Google Scholar 

  6. Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:1–7.

    Article  CAS  PubMed  Google Scholar 

  7. Wenzel J, Gerdsen R, Phillipp-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangrenosum. Dermatology. 2002;205:221–3.

    Article  CAS  PubMed  Google Scholar 

  8. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.

    Article  CAS  PubMed  Google Scholar 

  9. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–35.

    Article  CAS  PubMed  Google Scholar 

  10. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.

    Article  CAS  PubMed  Google Scholar 

  11. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37:1108–10.

    Article  CAS  PubMed  Google Scholar 

  12. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930–3.

    CAS  PubMed  Google Scholar 

  13. Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn’s disease: rapid cure with infliximab. Dermatology. 2002;205:278–80.

    Article  CAS  PubMed  Google Scholar 

  14. Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn’s disease. Acta Dermatovenerol Alp Panonica Adriat. 2006;15:173–7.

    PubMed  Google Scholar 

  15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.

    Article  CAS  PubMed  Google Scholar 

  16. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.

    Article  CAS  PubMed  Google Scholar 

  17. van Gestel AM, Prevoo ML, van ’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.

    Article  PubMed  Google Scholar 

  18. Bhat RM. Management of pyoderma gangrenosum—an update. Indian J Dermatol Venereol Leprol. 2004;70:329–35.

    PubMed  Google Scholar 

  19. McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol. 2004;3:441–4.

    PubMed  Google Scholar 

  20. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821–6.

    Article  CAS  PubMed  Google Scholar 

  21. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9.

    Article  CAS  PubMed  Google Scholar 

  22. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146–52.

    Article  CAS  PubMed  Google Scholar 

  23. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008;18:447–54.

    Article  CAS  PubMed  Google Scholar 

  24. Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T. Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Mod Rheumatol. 2009;19:166–72.

    Article  CAS  PubMed  Google Scholar 

  25. Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20:86–9.

    Article  PubMed  Google Scholar 

  26. Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26:2205–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Dr. Koike has received research grants and/or speaking fees from Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical. The other authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan

    Masahiro Tada, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani & Hiroaki Nakamura

  2. Department of Dermatology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan

    Takeshi Nakanishi & Chika Hirata

  3. Department of Rheumatosurgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan

    Tatsuya Koike

Authors
  1. Masahiro Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chika Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tadashi Okano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuko Sugioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shigeyuki Wakitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroaki Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatsuya Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tatsuya Koike.

About this article

Cite this article

Tada, M., Nakanishi, T., Hirata, C. et al. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Mod Rheumatol 20, 598–601 (2010). https://doi.org/10.1007/s10165-010-0336-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0336-0

Keywords

Search

Navigation